世界の腎除神経装置市場2022年-2028年:技術別(高周波、超音波、マイクロインフュージョン)、エンドユーザー別、製品種類別、地域別

【英語タイトル】Global Renal Denervation Market Size, Share & Industry Trends Analysis Report By Technology (Radiofrequency, Ultrasound, and Micro-Infusion), By End User, By Product Type By Regional Outlook and Forecast, 2022 – 2028

KBV Researchが出版した調査資料(KBV22JL156)・商品コード:KBV22JL156
・発行会社(調査会社):KBV Research
・発行日:2022年4月
・ページ数:206
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、英国、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、UAE、サウジアラビア、南アフリカ共和国、ナイジェリア
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,600 ⇒換算¥532,800見積依頼/購入/質問フォーム
Site License(同一拠点内で共有可)USD4,320 ⇒換算¥639,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

KBV Research社の本調査レポートでは、2021年におよそ14億ドルであった世界の腎除神経装置市場規模が、2022年から2028年の間に36.4%以上成長すると予測しています。本書では腎除神経装置の世界市場を調査対象にし、市場範囲・手法、市場動向、技術別(高周波、超音波、微量注入)分析、エンドユーザー別(病院、専門クリニック、その他)分析、製品種類別(Symplicity、Enlightn、Vessix、Paradise、その他)分析、地域別分析などを行っています。また、参入企業としてAbbott Laboratories、Boston Scientific Corporation、Medtronic PLC、Ablative Solutions, Inc.、Mercator MedSystems, Inc.、ReCor Medical, Inc.、Renal Dynamics Limited、Johnson & Johnson、Terumo Corporationなどの情報が含まれています。
・市場範囲・手法
・市場動向
・市場戦略
・世界の腎除神経装置市場規模:技術別(高周波、超音波、微量注入)
・世界の腎除神経装置市場規模:エンドユーザー別(病院、専門クリニック、その他)
・世界の腎除神経装置市場規模:製品種類別(Symplicity、Enlightn、Vessix、Paradise、その他)
・世界の腎除神経装置市場規模:地域別(北米、ヨーロッパ、アジア太平洋、南米・中東・アフリカ)
・企業情報

The Global Renal Denervation Market size is expected to reach $1.4 billion by 2028, rising at a market growth of 36.4% CAGR during the forecast period.

Renal denervation is a minimally invasive, catheter-based treatment for hypertension. The nerves in the renal arteries are burnt using radiofrequency ablation. Nerve activity is lowered, and blood pressure is reduced. When pharmacological treatment has failed to provide relief, this procedure is usually employed in order to obtain enhanced results. The nerves of the renal artery wall are ablated using radiofrequency pulses or ultrasound. This reduces blood pressure by lowering sympathetic kidney activity.

One of the key factors supporting market growth is a significant rising prevalence of lifestyle diseases, like hypertension, due to an increase in the number of people who smoke and drink alcohol, sedentary and hectic lifestyles, increasing unhealthy dietary patterns, and the surging geriatric population. Apart from that, the RDN system’s advantages, such as quick recuperation, safety, efficiency, and cost-effectiveness, are operating as a major growth-inducing element. Moreover, the rising demand for minimally invasive surgeries is fueling the market’s expansion. In addition, micro-infusion technology, improved healthcare infrastructure, increased research and development activities, and an increase in the number of files for regulatory approvals of the systems are all contributing to market expansion.

Ultrasound ablates nerves in the renal artery wall, interrupting nerve impulse transmission and decreasing blood pressure with ultrasound-based renal denervation devices. It is a hypertension treatment that is done with the least amount of invasiveness possible. Ultrasound-based technologies’ significant efficacy in trials is anticipated to rise their relevance and rejuvenate them. For example, ReCor Medical, a medical device manufacturer, debuted Paradise Ultrasound Renal Denervation for the therapeutics of hypertension in October 2021. This minimally invasive renal denervation technology is used to treat excessive blood pressure. Hence, the significant number of benefits of this method along with the increasing efforts and initiatives being introduced by major market players would accelerate the growth of the renal denervation market throughout the coming years.

COVID-19 Impact

The COVID-19 pandemic caused a severe impact on various economies all over the world. Several businesses were significantly devastated as a result of the outbreak of the COVID-19 infection. In addition, the governments of several countries were forced to impose lockdowns in their nations. As a result, the manufacturing units of numerous goods were temporarily shut down. Moreover, these lockdowns also caused a major disruption in the supply chain of various goods. Further, COVID-19 led the worldwide healthcare industry to a significant failure due to the shortage of beds and oxygen in hospitals.

Market Growth Factors

Rising instances of hypertension among people
With the increasing modernization all over the world, the lifestyles of people are majorly being altered. The day-to-day routines of people worldwide are increasingly becoming hectic. Hypertension is a significant and modifiable risk factor for cardiovascular disorders and diseases, chronic kidney disease, and death. Because more strict BP objectives are recommended by guidelines, obtaining these targets frequently necessitates the use of multiple drugs, which can result in increased dosing complexity, expense, pill burden, and drug intolerance. There are few choices for treating hypertension without worsening polypharmacy or in the presence of multidrug intolerance.

Introduction of new capabilities in Renal Denervation
The number of new capabilities that are being introduced in the renal denervation approach is one of the major factors that is accelerating its adoption. Renal denervation systems that incorporate ultrasound technology can overcome the limitations of radiofrequency-based renal denervation systems. The high-frequency sound waves of the ultrasonic energy aid to ablate nerves without coming into close touch with the tissues. This aids in the prevention of renal artery damage. Due to this attribute, a significant number of patients all over the world prefer this technology. Moreover, the integration of technology into these kinds of healthcare practices offers a considerable scale of enhancements in the outcomes of these techniques.

Market Restraining Factors

Risk of post-surgery infection
One of the major factors that are restricting the demand for renal denervation methods is the risk of infection that can be caused post a surgery. Any kind of surgery that involves cuts, incisions, or any other kind of invasion into the skin can cause infection in the body of the patient. Mostly, infections in surgical wounds are visible after one month of the surgery. Due to the post-surgical infection, various types of problems in the wound or in the body of the patient can occur. For example, surgical wound infections can ejaculate the puss from the incision. In addition, these infections are very painful and cause soars and inflammation in the wound.

Technology Outlook
Based on Technology, the market is segmented into Radiofrequency, Ultrasound, and Micro-Infusion. In 2021, the Ultrasound segment witnessed a significant revenue share of the renal denervation market. The ultrasound-based renal denervation devices employ ultrasound to ablate nerves in the walls of the renal arteries in a minimally invasive process. It reduces blood pressure by disrupting nerve impulse transmission to and from the kidney. Ultrasound energy in the form of high-frequency sound waves vaporizes nerves without making direct contact with tissues, minimizing renal artery damage. Due to the lesser damage to the renal artery in this method, the growth of the segment would significantly increase.

End User Outlook
Based on End User, the market is segmented into Hospitals, Specialty Clinics, and Others. In 2021, the Hospitals segment procured the largest revenue share of the real denervation market. The government’s increased investment in the construction of numerous specialty hospitals to combat the prevalence of dangerous diseases is boosting this segment’s growth. Additionally, hospitals are mostly staffed by professional practitioners, nurses, surgeons, and associated health practitioners, whereas in the past, this labor was typically handled by founding religious orders or volunteers.

Product Type Outlook
Based on Product Type, the market is segmented into Symplicity, Enlightn, Vessix, Paradise, Iberis, and Others. In 2021, the simplicity segment procured the largest revenue share of the renal denervation market. This device is most commonly used to treat hypertension because it delivers low-level radiofrequency energy, which reduces the risk of high-level radiofrequency causing radiation damage to body tissues. It also offers a minimally invasive method for treating high blood pressure. Due to the attribute that it causes lesser blood loss, the growth of this segment is estimated to flourish throughout the coming years.

Regional Outlook
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2021, Asia-Pacific witnessed a significant revenue share of the renal denervation market. In Asia-Pacific, due to a large number of unmet medical needs for hypertension therapy, increased knowledge of advanced technologies like renal denervation systems, and a high prevalence rate of resistant hypertension, there are numerous potential growth prospects for the market players. Therefore, the regional market would substantially grow throughout the coming years.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Ablative Solutions, Inc., Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, Johnson & Johnson, and Terumo Corporation.

Strategies deployed in Renal Denervation Market

Jan-2022: Johnson & Johnson teamed up with Microsoft, an American multinational technology corporation. Under this collaboration, Johnson & Johnson would leverage cloud computing services of Microsoft in order to establish a connection between patients and surgeons in a digital surgery ecosystem.

Oct-2021: ReCor Medical introduced Paradise Ultrasound Renal Denervation System. The new product would streamline the diagnosis of uncontrolled hypertension in patients across Germany.

Apr-2021: Medtronic partnered with Surgical Theater, a developer of technology based on fighter jet flight simulation for patient. Following this partnership, the Medtronic would integrate its StealthStation S8 surgical navigation system into Surgical Theater’s SyncAR augmented reality technology with the purpose to allow neurosurgeons to leverage AR technology in real-time in order to improve visualization during sophisticated cranial procedures.

Jan-2019: Terumo took over Essen Technology, a medical device company based in China. Through this acquisition, the company aimed to expand its geographical footprint across Chinese market in order to address the rising demand for domestic products with its domestically manufactured DES.

Scope of the Study

Market Segments covered in the Report:

By Technology
• Radiofrequency
• Ultrasound
• Micro-Infusion

By End User
• Hospitals
• Specialty Clinics
• Others

By Product Type
• Symplicity
• Enlightn
• Vessix
• Paradise
• Iberis
• Others

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic PLC
• Ablative Solutions, Inc.
• Mercator MedSystems, Inc.
• ReCor Medical, Inc.
• Renal Dynamics Limited
• Johnson & Johnson
• Terumo Corporation

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

❖ レポートの目次 ❖

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Renal Denervation Market, by Technology
1.4.2 Global Renal Denervation Market, by End User
1.4.3 Global Renal Denervation Market, by Product Type
1.4.4 Global Renal Denervation Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Renal Denervation Market by Technology
3.1 Global Radiofrequency Market by Region
3.2 Global Ultrasound Market by Region
3.3 Global Micro-Infusion Market by Region
Chapter 4. Global Renal Denervation Market by End User
4.1 Global Hospitals Market by Region
4.2 Global Specialty Clinics Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Renal Denervation Market by Product Type
5.1 Global Symplicity Market by Region
5.2 Global Enlightn Market by Region
5.3 Global Vessix Market by Region
5.4 Global Paradise Market by Region
5.5 Global Iberis Market by Region
5.6 Global Others Market by Region
Chapter 6. Global Renal Denervation Market by Region
6.1 North America Renal Denervation Market
6.1.1 North America Renal Denervation Market by Technology
6.1.1.1 North America Radiofrequency Market by Country
6.1.1.2 North America Ultrasound Market by Country
6.1.1.3 North America Micro-Infusion Market by Country
6.1.2 North America Renal Denervation Market by End User
6.1.2.1 North America Hospitals Market by Country
6.1.2.2 North America Specialty Clinics Market by Country
6.1.2.3 North America Others Market by Country
6.1.3 North America Renal Denervation Market by Product Type
6.1.3.1 North America Symplicity Market by Country
6.1.3.2 North America Enlightn Market by Country
6.1.3.3 North America Vessix Market by Country
6.1.3.4 North America Paradise Market by Country
6.1.3.5 North America Iberis Market by Country
6.1.3.6 North America Others Market by Country
6.1.4 North America Renal Denervation Market by Country
6.1.4.1 US Renal Denervation Market
6.1.4.1.1 US Renal Denervation Market by Technology
6.1.4.1.2 US Renal Denervation Market by End User
6.1.4.1.3 US Renal Denervation Market by Product Type
6.1.4.2 Canada Renal Denervation Market
6.1.4.2.1 Canada Renal Denervation Market by Technology
6.1.4.2.2 Canada Renal Denervation Market by End User
6.1.4.2.3 Canada Renal Denervation Market by Product Type
6.1.4.3 Mexico Renal Denervation Market
6.1.4.3.1 Mexico Renal Denervation Market by Technology
6.1.4.3.2 Mexico Renal Denervation Market by End User
6.1.4.3.3 Mexico Renal Denervation Market by Product Type
6.1.4.4 Rest of North America Renal Denervation Market
6.1.4.4.1 Rest of North America Renal Denervation Market by Technology
6.1.4.4.2 Rest of North America Renal Denervation Market by End User
6.1.4.4.3 Rest of North America Renal Denervation Market by Product Type
6.2 Europe Renal Denervation Market
6.2.1 Europe Renal Denervation Market by Technology
6.2.1.1 Europe Radiofrequency Market by Country
6.2.1.2 Europe Ultrasound Market by Country
6.2.1.3 Europe Micro-Infusion Market by Country
6.2.2 Europe Renal Denervation Market by End User
6.2.2.1 Europe Hospitals Market by Country
6.2.2.2 Europe Specialty Clinics Market by Country
6.2.2.3 Europe Others Market by Country
6.2.3 Europe Renal Denervation Market by Product Type
6.2.3.1 Europe Symplicity Market by Country
6.2.3.2 Europe Enlightn Market by Country
6.2.3.3 Europe Vessix Market by Country
6.2.3.4 Europe Paradise Market by Country
6.2.3.5 Europe Iberis Market by Country
6.2.3.6 Europe Others Market by Country
6.2.4 Europe Renal Denervation Market by Country
6.2.4.1 Germany Renal Denervation Market
6.2.4.1.1 Germany Renal Denervation Market by Technology
6.2.4.1.2 Germany Renal Denervation Market by End User
6.2.4.1.3 Germany Renal Denervation Market by Product Type
6.2.4.2 UK Renal Denervation Market
6.2.4.2.1 UK Renal Denervation Market by Technology
6.2.4.2.2 UK Renal Denervation Market by End User
6.2.4.2.3 UK Renal Denervation Market by Product Type
6.2.4.3 France Renal Denervation Market
6.2.4.3.1 France Renal Denervation Market by Technology
6.2.4.3.2 France Renal Denervation Market by End User
6.2.4.3.3 France Renal Denervation Market by Product Type
6.2.4.4 Russia Renal Denervation Market
6.2.4.4.1 Russia Renal Denervation Market by Technology
6.2.4.4.2 Russia Renal Denervation Market by End User
6.2.4.4.3 Russia Renal Denervation Market by Product Type
6.2.4.5 Spain Renal Denervation Market
6.2.4.5.1 Spain Renal Denervation Market by Technology
6.2.4.5.2 Spain Renal Denervation Market by End User
6.2.4.5.3 Spain Renal Denervation Market by Product Type
6.2.4.6 Italy Renal Denervation Market
6.2.4.6.1 Italy Renal Denervation Market by Technology
6.2.4.6.2 Italy Renal Denervation Market by End User
6.2.4.6.3 Italy Renal Denervation Market by Product Type
6.2.4.7 Rest of Europe Renal Denervation Market
6.2.4.7.1 Rest of Europe Renal Denervation Market by Technology
6.2.4.7.2 Rest of Europe Renal Denervation Market by End User
6.2.4.7.3 Rest of Europe Renal Denervation Market by Product Type
6.3 Asia Pacific Renal Denervation Market
6.3.1 Asia Pacific Renal Denervation Market by Technology
6.3.1.1 Asia Pacific Radiofrequency Market by Country
6.3.1.2 Asia Pacific Ultrasound Market by Country
6.3.1.3 Asia Pacific Micro-Infusion Market by Country
6.3.2 Asia Pacific Renal Denervation Market by End User
6.3.2.1 Asia Pacific Hospitals Market by Country
6.3.2.2 Asia Pacific Specialty Clinics Market by Country
6.3.2.3 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Renal Denervation Market by Product Type
6.3.3.1 Asia Pacific Symplicity Market by Country
6.3.3.2 Asia Pacific Enlightn Market by Country
6.3.3.3 Asia Pacific Vessix Market by Country
6.3.3.4 Asia Pacific Paradise Market by Country
6.3.3.5 Asia Pacific Iberis Market by Country
6.3.3.6 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Renal Denervation Market by Country
6.3.4.1 China Renal Denervation Market
6.3.4.1.1 China Renal Denervation Market by Technology
6.3.4.1.2 China Renal Denervation Market by End User
6.3.4.1.3 China Renal Denervation Market by Product Type
6.3.4.2 Japan Renal Denervation Market
6.3.4.2.1 Japan Renal Denervation Market by Technology
6.3.4.2.2 Japan Renal Denervation Market by End User
6.3.4.2.3 Japan Renal Denervation Market by Product Type
6.3.4.3 India Renal Denervation Market
6.3.4.3.1 India Renal Denervation Market by Technology
6.3.4.3.2 India Renal Denervation Market by End User
6.3.4.3.3 India Renal Denervation Market by Product Type
6.3.4.4 South Korea Renal Denervation Market
6.3.4.4.1 South Korea Renal Denervation Market by Technology
6.3.4.4.2 South Korea Renal Denervation Market by End User
6.3.4.4.3 South Korea Renal Denervation Market by Product Type
6.3.4.5 Singapore Renal Denervation Market
6.3.4.5.1 Singapore Renal Denervation Market by Technology
6.3.4.5.2 Singapore Renal Denervation Market by End User
6.3.4.5.3 Singapore Renal Denervation Market by Product Type
6.3.4.6 Malaysia Renal Denervation Market
6.3.4.6.1 Malaysia Renal Denervation Market by Technology
6.3.4.6.2 Malaysia Renal Denervation Market by End User
6.3.4.6.3 Malaysia Renal Denervation Market by Product Type
6.3.4.7 Rest of Asia Pacific Renal Denervation Market
6.3.4.7.1 Rest of Asia Pacific Renal Denervation Market by Technology
6.3.4.7.2 Rest of Asia Pacific Renal Denervation Market by End User
6.3.4.7.3 Rest of Asia Pacific Renal Denervation Market by Product Type
6.4 LAMEA Renal Denervation Market
6.4.1 LAMEA Renal Denervation Market by Technology
6.4.1.1 LAMEA Radiofrequency Market by Country
6.4.1.2 LAMEA Ultrasound Market by Country
6.4.1.3 LAMEA Micro-Infusion Market by Country
6.4.2 LAMEA Renal Denervation Market by End User
6.4.2.1 LAMEA Hospitals Market by Country
6.4.2.2 LAMEA Specialty Clinics Market by Country
6.4.2.3 LAMEA Others Market by Country
6.4.3 LAMEA Renal Denervation Market by Product Type
6.4.3.1 LAMEA Symplicity Market by Country
6.4.3.2 LAMEA Enlightn Market by Country
6.4.3.3 LAMEA Vessix Market by Country
6.4.3.4 LAMEA Paradise Market by Country
6.4.3.5 LAMEA Iberis Market by Country
6.4.3.6 LAMEA Others Market by Country
6.4.4 LAMEA Renal Denervation Market by Country
6.4.4.1 Brazil Renal Denervation Market
6.4.4.1.1 Brazil Renal Denervation Market by Technology
6.4.4.1.2 Brazil Renal Denervation Market by End User
6.4.4.1.3 Brazil Renal Denervation Market by Product Type
6.4.4.2 Argentina Renal Denervation Market
6.4.4.2.1 Argentina Renal Denervation Market by Technology
6.4.4.2.2 Argentina Renal Denervation Market by End User
6.4.4.2.3 Argentina Renal Denervation Market by Product Type
6.4.4.3 UAE Renal Denervation Market
6.4.4.3.1 UAE Renal Denervation Market by Technology
6.4.4.3.2 UAE Renal Denervation Market by End User
6.4.4.3.3 UAE Renal Denervation Market by Product Type
6.4.4.4 Saudi Arabia Renal Denervation Market
6.4.4.4.1 Saudi Arabia Renal Denervation Market by Technology
6.4.4.4.2 Saudi Arabia Renal Denervation Market by End User
6.4.4.4.3 Saudi Arabia Renal Denervation Market by Product Type
6.4.4.5 South Africa Renal Denervation Market
6.4.4.5.1 South Africa Renal Denervation Market by Technology
6.4.4.5.2 South Africa Renal Denervation Market by End User
6.4.4.5.3 South Africa Renal Denervation Market by Product Type
6.4.4.6 Nigeria Renal Denervation Market
6.4.4.6.1 Nigeria Renal Denervation Market by Technology
6.4.4.6.2 Nigeria Renal Denervation Market by End User
6.4.4.6.3 Nigeria Renal Denervation Market by Product Type
6.4.4.7 Rest of LAMEA Renal Denervation Market
6.4.4.7.1 Rest of LAMEA Renal Denervation Market by Technology
6.4.4.7.2 Rest of LAMEA Renal Denervation Market by End User
6.4.4.7.3 Rest of LAMEA Renal Denervation Market by Product Type
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Boston Scientific Corporation
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Medtronic PLC
7.3.1 Company overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, Collaborations, and Agreements:
7.4 Ablative Solutions, Inc.
7.4.1 Company Overview
7.5 Mercator MedSystems, Inc.
7.5.1 Company Overview
7.6 ReCor Medical, Inc (Otsuka Holdings Co., Ltd.)
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Product Launches and Product Expansions:
7.7 Renal Dynamics Limited
7.7.1 Company Overview
7.8 Johnson & Johnson
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental &Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations and Agreements:
7.9 Terumo Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental Analysis
7.9.4 Recent strategies and developments:
7.9.4.1 Acquisition and Mergers:



★調査レポート[世界の腎除神経装置市場2022年-2028年:技術別(高周波、超音波、マイクロインフュージョン)、エンドユーザー別、製品種類別、地域別] (コード:KBV22JL156)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の腎除神経装置市場2022年-2028年:技術別(高周波、超音波、マイクロインフュージョン)、エンドユーザー別、製品種類別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆